Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

Dr. Sanjay Popat, Phd, with Royal Marden Hospital, comments on Abrstract Presentation: Results from a Phase II single-agent trial.<br /><br />Background: Lurbinectedin (L) is a novel anticancer drug that inhi... Author: Annual-Meeting Added: 06/07/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts